Targeting Estrogen Receptor Beta in a Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer: A Wisconsin Oncology Network Study

BACKGROUND: Estrogen receptor beta (ERβ) is expressed by 50-80% of triple negative breast cancers (TNBC). Agonism of ERβ has antiproliferative effects in TNBC cells expressing ERβ. This phase II study evaluated single agent high dose estradiol in patients with advanced TNBC. PATIENTS AND METHODS: Ad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Breast Cancer
Main Authors: Wisinski, Kari B., Xu, Wei, Tevaarwerk, Amye J., Saha, Sandeep, Kim, KyungMann, Traynor, Anne, Dietrich, Leah, Hegeman, Robert, Patel, Dhimant, Blank, Jules, Harter, Josephine, Burkard, Mark E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4969205/
https://ncbi.nlm.nih.gov/pubmed/27133732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2016.03.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados